(R)-Carisbamate (C₉H₁₀N₂O₃, MW 194.19) is a chiral synthetic organic compound and specialty research chemical (≥95% purity). It was investigated as a potential anticonvulsant for epilepsy and other CNS disorders due to its ability to modulate neuronal excitability via a unique mechanism distinct from other antiepileptic drugs. It also showed promise in preclinical studies for neuropathic pain relief and neuroprotection in conditions like stroke or neurodegenerative diseases. Although clinical development was discontinued by Johnson & Johnson in 2009 after phase III trials failed to demonstrate sufficient efficacy, it remains valuable in laboratory research for refractory epilepsy models, pain signaling pathways, and neuroprotective studies.